Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in HFrEF (EMPEROR-Reduced)
NCT03057977Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2017
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of empagliflozin in heart failure with reduced ejection fraction (HFrEF), sponsored by Boehringer Ingelheim. Started Mar 2017; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT03057977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03057977.